Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO-B) Stock Competitors & Peer Comparison
See (BIO-B) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO-B | $247.05 | +0.00% | 6.8B | -3.23 | -$76.53 | N/A |
| ABT | $127.29 | +0.87% | 221.5B | 15.95 | $7.98 | +1.82% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $105.41 | +0.47% | 155.9B | 62.73 | $1.68 | N/A |
| SYK | $377.79 | -3.80% | 144.5B | 50.13 | $7.54 | +0.88% |
| MDT | $89.34 | -1.00% | 114.4B | 24.74 | $3.61 | +3.15% |
| EW | $79.33 | +0.03% | 46.5B | 33.19 | $2.39 | N/A |
| DXCM | $79.28 | -1.84% | 31.1B | 55.83 | $1.42 | N/A |
| PHG | $26.46 | +0.99% | 25.1B | 146.92 | $0.18 | +3.36% |
| STE | $226.87 | +0.17% | 22.3B | 36.84 | $6.16 | +1.01% |
Stock Comparison
BIO-B vs ABT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ABT has a market cap of 221.5B. Regarding current trading prices, BIO-B is priced at $247.05, while ABT trades at $127.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ABT's P/E ratio is 15.95. In terms of profitability, BIO-B's ROE is +0.05%, compared to ABT's ROE of +0.32%. Regarding short-term risk, BIO-B is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ABT's competition here
BIO-B vs BSX-PA Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO-B is priced at $247.05, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO-B's ROE is +0.05%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSX-PA's competition here
BIO-B vs BSX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BSX has a market cap of 155.9B. Regarding current trading prices, BIO-B is priced at $247.05, while BSX trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BSX's P/E ratio is 62.73. In terms of profitability, BIO-B's ROE is +0.05%, compared to BSX's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSX's competition here
BIO-B vs SYK Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SYK has a market cap of 144.5B. Regarding current trading prices, BIO-B is priced at $247.05, while SYK trades at $377.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SYK's P/E ratio is 50.13. In terms of profitability, BIO-B's ROE is +0.05%, compared to SYK's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SYK's competition here
BIO-B vs MDT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, MDT has a market cap of 114.4B. Regarding current trading prices, BIO-B is priced at $247.05, while MDT trades at $89.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas MDT's P/E ratio is 24.74. In terms of profitability, BIO-B's ROE is +0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MDT's competition here
BIO-B vs EW Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, EW has a market cap of 46.5B. Regarding current trading prices, BIO-B is priced at $247.05, while EW trades at $79.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas EW's P/E ratio is 33.19. In terms of profitability, BIO-B's ROE is +0.05%, compared to EW's ROE of +0.45%. Regarding short-term risk, BIO-B is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EW's competition here
BIO-B vs DXCM Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, DXCM has a market cap of 31.1B. Regarding current trading prices, BIO-B is priced at $247.05, while DXCM trades at $79.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas DXCM's P/E ratio is 55.83. In terms of profitability, BIO-B's ROE is +0.05%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, BIO-B is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check DXCM's competition here
BIO-B vs PHG Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, PHG has a market cap of 25.1B. Regarding current trading prices, BIO-B is priced at $247.05, while PHG trades at $26.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas PHG's P/E ratio is 146.92. In terms of profitability, BIO-B's ROE is +0.05%, compared to PHG's ROE of +0.03%. Regarding short-term risk, BIO-B is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PHG's competition here
BIO-B vs STE Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, STE has a market cap of 22.3B. Regarding current trading prices, BIO-B is priced at $247.05, while STE trades at $226.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas STE's P/E ratio is 36.84. In terms of profitability, BIO-B's ROE is +0.05%, compared to STE's ROE of +0.09%. Regarding short-term risk, BIO-B is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check STE's competition here
BIO-B vs PODD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, PODD has a market cap of 20.1B. Regarding current trading prices, BIO-B is priced at $247.05, while PODD trades at $284.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas PODD's P/E ratio is 51.34. In terms of profitability, BIO-B's ROE is +0.05%, compared to PODD's ROE of +0.35%. Regarding short-term risk, BIO-B is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PODD's competition here
BIO-B vs ZBH Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ZBH has a market cap of 17.9B. Regarding current trading prices, BIO-B is priced at $247.05, while ZBH trades at $90.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ZBH's P/E ratio is 20.13. In terms of profitability, BIO-B's ROE is +0.05%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, BIO-B is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ZBH's competition here
BIO-B vs ABMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO-B is priced at $247.05, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO-B's ROE is +0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ABMD's competition here
BIO-B vs SNN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, BIO-B is priced at $247.05, while SNN trades at $30.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SNN's P/E ratio is 32.82. In terms of profitability, BIO-B's ROE is +0.05%, compared to SNN's ROE of +0.08%. Regarding short-term risk, BIO-B is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SNN's competition here
BIO-B vs SWAV Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $247.05, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO-B's ROE is +0.05%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, BIO-B is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SWAV's competition here
BIO-B vs ALGN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ALGN has a market cap of 9.9B. Regarding current trading prices, BIO-B is priced at $247.05, while ALGN trades at $136.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ALGN's P/E ratio is 23.06. In terms of profitability, BIO-B's ROE is +0.05%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ALGN's competition here
BIO-B vs PEN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, PEN has a market cap of 9.5B. Regarding current trading prices, BIO-B is priced at $247.05, while PEN trades at $243.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas PEN's P/E ratio is 64.08. In terms of profitability, BIO-B's ROE is +0.05%, compared to PEN's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PEN's competition here
BIO-B vs BIO Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, BIO-B is priced at $247.05, while BIO trades at $284.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BIO's P/E ratio is -3.72. In terms of profitability, BIO-B's ROE is +0.05%, compared to BIO's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BIO's competition here
BIO-B vs GMED Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, GMED has a market cap of 7.1B. Regarding current trading prices, BIO-B is priced at $247.05, while GMED trades at $52.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas GMED's P/E ratio is 39.28. In terms of profitability, BIO-B's ROE is +0.05%, compared to GMED's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check GMED's competition here
BIO-B vs BRKR Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, BIO-B is priced at $247.05, while BRKR trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BRKR's P/E ratio is 73.02. In terms of profitability, BIO-B's ROE is +0.05%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, BIO-B is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BRKR's competition here
BIO-B vs IRTC Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, IRTC has a market cap of 5.3B. Regarding current trading prices, BIO-B is priced at $247.05, while IRTC trades at $164.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas IRTC's P/E ratio is -52.71. In terms of profitability, BIO-B's ROE is +0.05%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, BIO-B is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IRTC's competition here
BIO-B vs GKOS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, GKOS has a market cap of 4.9B. Regarding current trading prices, BIO-B is priced at $247.05, while GKOS trades at $86.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas GKOS's P/E ratio is -53.51. In terms of profitability, BIO-B's ROE is +0.05%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check GKOS's competition here
BIO-B vs NARI Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO-B is priced at $247.05, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO-B's ROE is +0.05%, compared to NARI's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NARI's competition here
BIO-B vs TMDX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, TMDX has a market cap of 4.1B. Regarding current trading prices, BIO-B is priced at $247.05, while TMDX trades at $120.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas TMDX's P/E ratio is 60.58. In terms of profitability, BIO-B's ROE is +0.05%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, BIO-B is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TMDX's competition here
BIO-B vs ITGR Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ITGR has a market cap of 3.7B. Regarding current trading prices, BIO-B is priced at $247.05, while ITGR trades at $106.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ITGR's P/E ratio is 45.47. In terms of profitability, BIO-B's ROE is +0.05%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ITGR's competition here
BIO-B vs INSP Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, INSP has a market cap of 3.7B. Regarding current trading prices, BIO-B is priced at $247.05, while INSP trades at $126.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas INSP's P/E ratio is 57.54. In terms of profitability, BIO-B's ROE is +0.05%, compared to INSP's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INSP's competition here
BIO-B vs AXNX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO-B is priced at $247.05, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO-B's ROE is +0.05%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO-B and AXNX have similar daily volatility (0.00).Check AXNX's competition here
BIO-B vs PRCT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, PRCT has a market cap of 2.8B. Regarding current trading prices, BIO-B is priced at $247.05, while PRCT trades at $49.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas PRCT's P/E ratio is -29.56. In terms of profitability, BIO-B's ROE is +0.05%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, BIO-B is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PRCT's competition here
BIO-B vs LIVN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, LIVN has a market cap of 2.2B. Regarding current trading prices, BIO-B is priced at $247.05, while LIVN trades at $41.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas LIVN's P/E ratio is -10.11. In terms of profitability, BIO-B's ROE is +0.05%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LIVN's competition here
BIO-B vs NUVA Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO-B is priced at $247.05, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO-B's ROE is +0.05%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NUVA's competition here
BIO-B vs ATEC Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ATEC has a market cap of 2B. Regarding current trading prices, BIO-B is priced at $247.05, while ATEC trades at $13.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ATEC's P/E ratio is -12.08. In terms of profitability, BIO-B's ROE is +0.05%, compared to ATEC's ROE of -2.77%. Regarding short-term risk, BIO-B is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ATEC's competition here
BIO-B vs UFPT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, BIO-B is priced at $247.05, while UFPT trades at $226.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas UFPT's P/E ratio is 27.80. In terms of profitability, BIO-B's ROE is +0.05%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, BIO-B is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check UFPT's competition here
BIO-B vs CNMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, BIO-B is priced at $247.05, while CNMD trades at $52.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CNMD's P/E ratio is 14.78. In terms of profitability, BIO-B's ROE is +0.05%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CNMD's competition here
BIO-B vs AORT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $247.05, while AORT trades at $30.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas AORT's P/E ratio is -60.67. In terms of profitability, BIO-B's ROE is +0.05%, compared to AORT's ROE of -0.07%. Regarding short-term risk, BIO-B is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AORT's competition here
BIO-B vs HSKA Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $247.05, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO-B's ROE is +0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO-B and HSKA have similar daily volatility (0.00).Check HSKA's competition here
BIO-B vs SSII Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SSII has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $247.05, while SSII trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SSII's P/E ratio is -77.50. In terms of profitability, BIO-B's ROE is +0.05%, compared to SSII's ROE of -1.05%. Regarding short-term risk, BIO-B is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SSII's competition here
BIO-B vs ESTA Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $247.05, while ESTA trades at $41.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ESTA's P/E ratio is -13.25. In terms of profitability, BIO-B's ROE is +0.05%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, BIO-B is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ESTA's competition here
BIO-B vs AHCO Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $247.05, while AHCO trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas AHCO's P/E ratio is 15.09. In terms of profitability, BIO-B's ROE is +0.05%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AHCO's competition here
BIO-B vs SILK Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $247.05, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO-B's ROE is +0.05%, compared to SILK's ROE of -0.29%. Regarding short-term risk, BIO-B is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SILK's competition here
BIO-B vs FNA Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $247.05, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO-B's ROE is +0.05%, compared to FNA's ROE of -0.36%. Regarding short-term risk, BIO-B is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check FNA's competition here
BIO-B vs TNDM Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, BIO-B is priced at $247.05, while TNDM trades at $15.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas TNDM's P/E ratio is -5.52. In terms of profitability, BIO-B's ROE is +0.05%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, BIO-B is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TNDM's competition here
BIO-B vs IART Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, IART has a market cap of 956.6M. Regarding current trading prices, BIO-B is priced at $247.05, while IART trades at $12.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas IART's P/E ratio is -1.88. In terms of profitability, BIO-B's ROE is +0.05%, compared to IART's ROE of -0.44%. Regarding short-term risk, BIO-B is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IART's competition here
BIO-B vs INMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, INMD has a market cap of 955.7M. Regarding current trading prices, BIO-B is priced at $247.05, while INMD trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas INMD's P/E ratio is 5.77. In terms of profitability, BIO-B's ROE is +0.05%, compared to INMD's ROE of +0.27%. Regarding short-term risk, BIO-B is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INMD's competition here
BIO-B vs CSII Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO-B is priced at $247.05, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO-B's ROE is +0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO-B is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CSII's competition here
BIO-B vs IRMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, IRMD has a market cap of 841.4M. Regarding current trading prices, BIO-B is priced at $247.05, while IRMD trades at $66.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas IRMD's P/E ratio is 42.69. In terms of profitability, BIO-B's ROE is +0.05%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIO-B is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IRMD's competition here
BIO-B vs SMLR Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SMLR has a market cap of 799M. Regarding current trading prices, BIO-B is priced at $247.05, while SMLR trades at $34.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SMLR's P/E ratio is -14.42. In terms of profitability, BIO-B's ROE is +0.05%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SMLR's competition here
BIO-B vs SIBN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SIBN has a market cap of 741.1M. Regarding current trading prices, BIO-B is priced at $247.05, while SIBN trades at $17.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SIBN's P/E ratio is -27.60. In terms of profitability, BIO-B's ROE is +0.05%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, BIO-B is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SIBN's competition here
BIO-B vs CRY Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BIO-B is priced at $247.05, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CRY's P/E ratio is 425.71. In terms of profitability, BIO-B's ROE is +0.05%, compared to CRY's ROE of -0.07%. Regarding short-term risk, BIO-B is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CRY's competition here
BIO-B vs APEN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO-B is priced at $247.05, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO-B's ROE is +0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO-B is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check APEN's competition here
BIO-B vs AXGN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, AXGN has a market cap of 577M. Regarding current trading prices, BIO-B is priced at $247.05, while AXGN trades at $12.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas AXGN's P/E ratio is -79.19. In terms of profitability, BIO-B's ROE is +0.05%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, BIO-B is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AXGN's competition here
BIO-B vs ZIMV Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ZIMV has a market cap of 529M. Regarding current trading prices, BIO-B is priced at $247.05, while ZIMV trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ZIMV's P/E ratio is -20.84. In terms of profitability, BIO-B's ROE is +0.05%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, BIO-B is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ZIMV's competition here
BIO-B vs SRDX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SRDX has a market cap of 515.2M. Regarding current trading prices, BIO-B is priced at $247.05, while SRDX trades at $36.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SRDX's P/E ratio is -25.74. In terms of profitability, BIO-B's ROE is +0.05%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, BIO-B is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SRDX's competition here
BIO-B vs CBLL Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CBLL has a market cap of 511.1M. Regarding current trading prices, BIO-B is priced at $247.05, while CBLL trades at $14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CBLL's P/E ratio is -11.31. In terms of profitability, BIO-B's ROE is +0.05%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, BIO-B is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CBLL's competition here
BIO-B vs AVNS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, AVNS has a market cap of 508.2M. Regarding current trading prices, BIO-B is priced at $247.05, while AVNS trades at $10.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas AVNS's P/E ratio is -1.33. In terms of profitability, BIO-B's ROE is +0.05%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, BIO-B is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AVNS's competition here
BIO-B vs KIDS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, KIDS has a market cap of 505M. Regarding current trading prices, BIO-B is priced at $247.05, while KIDS trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas KIDS's P/E ratio is -11.59. In terms of profitability, BIO-B's ROE is +0.05%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BIO-B is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check KIDS's competition here
BIO-B vs CTKB Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CTKB has a market cap of 461M. Regarding current trading prices, BIO-B is priced at $247.05, while CTKB trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CTKB's P/E ratio is -40.44. In terms of profitability, BIO-B's ROE is +0.05%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, BIO-B is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CTKB's competition here
BIO-B vs OFIX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, OFIX has a market cap of 422M. Regarding current trading prices, BIO-B is priced at $247.05, while OFIX trades at $10.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas OFIX's P/E ratio is -2.91. In terms of profitability, BIO-B's ROE is +0.05%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, BIO-B is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check OFIX's competition here
BIO-B vs BVS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BVS has a market cap of 410.1M. Regarding current trading prices, BIO-B is priced at $247.05, while BVS trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BVS's P/E ratio is -12.87. In terms of profitability, BIO-B's ROE is +0.05%, compared to BVS's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BVS's competition here
BIO-B vs PACB Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, PACB has a market cap of 399.1M. Regarding current trading prices, BIO-B is priced at $247.05, while PACB trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas PACB's P/E ratio is -0.49. In terms of profitability, BIO-B's ROE is +0.05%, compared to PACB's ROE of -1.70%. Regarding short-term risk, BIO-B is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PACB's competition here
BIO-B vs SENS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SENS has a market cap of 364.9M. Regarding current trading prices, BIO-B is priced at $247.05, while SENS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SENS's P/E ratio is -4.40. In terms of profitability, BIO-B's ROE is +0.05%, compared to SENS's ROE of -7.46%. Regarding short-term risk, BIO-B is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SENS's competition here
BIO-B vs BFLY Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BFLY has a market cap of 346M. Regarding current trading prices, BIO-B is priced at $247.05, while BFLY trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BFLY's P/E ratio is -4.66. In terms of profitability, BIO-B's ROE is +0.05%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, BIO-B is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BFLY's competition here
BIO-B vs TMCI Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, TMCI has a market cap of 335.9M. Regarding current trading prices, BIO-B is priced at $247.05, while TMCI trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas TMCI's P/E ratio is -6.28. In terms of profitability, BIO-B's ROE is +0.05%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, BIO-B is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TMCI's competition here
BIO-B vs RXST Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, RXST has a market cap of 317M. Regarding current trading prices, BIO-B is priced at $247.05, while RXST trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas RXST's P/E ratio is -11.82. In terms of profitability, BIO-B's ROE is +0.05%, compared to RXST's ROE of -0.10%. Regarding short-term risk, BIO-B is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RXST's competition here
BIO-B vs SNWV Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SNWV has a market cap of 310.6M. Regarding current trading prices, BIO-B is priced at $247.05, while SNWV trades at $36.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SNWV's P/E ratio is -5.82. In terms of profitability, BIO-B's ROE is +0.05%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, BIO-B is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SNWV's competition here
BIO-B vs VREX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, VREX has a market cap of 298M. Regarding current trading prices, BIO-B is priced at $247.05, while VREX trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas VREX's P/E ratio is -6.97. In terms of profitability, BIO-B's ROE is +0.05%, compared to VREX's ROE of -0.08%. Regarding short-term risk, BIO-B is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check VREX's competition here
BIO-B vs NPCE Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, NPCE has a market cap of 294.9M. Regarding current trading prices, BIO-B is priced at $247.05, while NPCE trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas NPCE's P/E ratio is -10.96. In terms of profitability, BIO-B's ROE is +0.05%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, BIO-B is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NPCE's competition here
BIO-B vs NNOX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, NNOX has a market cap of 293.3M. Regarding current trading prices, BIO-B is priced at $247.05, while NNOX trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas NNOX's P/E ratio is -5.05. In terms of profitability, BIO-B's ROE is +0.05%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, BIO-B is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NNOX's competition here
BIO-B vs CLPT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CLPT has a market cap of 282.7M. Regarding current trading prices, BIO-B is priced at $247.05, while CLPT trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CLPT's P/E ratio is -13.16. In terms of profitability, BIO-B's ROE is +0.05%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, BIO-B is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CLPT's competition here
BIO-B vs QTRX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, QTRX has a market cap of 273.4M. Regarding current trading prices, BIO-B is priced at $247.05, while QTRX trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas QTRX's P/E ratio is -4.73. In terms of profitability, BIO-B's ROE is +0.05%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, BIO-B is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check QTRX's competition here
BIO-B vs CATX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CATX has a market cap of 272.4M. Regarding current trading prices, BIO-B is priced at $247.05, while CATX trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CATX's P/E ratio is -2.98. In terms of profitability, BIO-B's ROE is +0.05%, compared to CATX's ROE of -0.27%. Regarding short-term risk, BIO-B is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CATX's competition here
BIO-B vs OM Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, OM has a market cap of 266.5M. Regarding current trading prices, BIO-B is priced at $247.05, while OM trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas OM's P/E ratio is -0.52. In terms of profitability, BIO-B's ROE is +0.05%, compared to OM's ROE of -1.45%. Regarding short-term risk, BIO-B is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check OM's competition here
BIO-B vs BFLY-WT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BFLY-WT has a market cap of 249.1M. Regarding current trading prices, BIO-B is priced at $247.05, while BFLY-WT trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.05%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, BIO-B is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BFLY-WT's competition here
BIO-B vs CERS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CERS has a market cap of 239.9M. Regarding current trading prices, BIO-B is priced at $247.05, while CERS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CERS's P/E ratio is -12.55. In terms of profitability, BIO-B's ROE is +0.05%, compared to CERS's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CERS's competition here
BIO-B vs VMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, VMD has a market cap of 234.4M. Regarding current trading prices, BIO-B is priced at $247.05, while VMD trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas VMD's P/E ratio is 19.77. In terms of profitability, BIO-B's ROE is +0.05%, compared to VMD's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check VMD's competition here
BIO-B vs MASS Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, MASS has a market cap of 230.2M. Regarding current trading prices, BIO-B is priced at $247.05, while MASS trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas MASS's P/E ratio is -2.89. In terms of profitability, BIO-B's ROE is +0.05%, compared to MASS's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MASS's competition here
BIO-B vs TCMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, TCMD has a market cap of 224.3M. Regarding current trading prices, BIO-B is priced at $247.05, while TCMD trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas TCMD's P/E ratio is 14.62. In terms of profitability, BIO-B's ROE is +0.05%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, BIO-B is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TCMD's competition here
BIO-B vs NVRO Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO-B is priced at $247.05, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO-B's ROE is +0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO-B is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NVRO's competition here
BIO-B vs MXCT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, MXCT has a market cap of 216.9M. Regarding current trading prices, BIO-B is priced at $247.05, while MXCT trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas MXCT's P/E ratio is -5.10. In terms of profitability, BIO-B's ROE is +0.05%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, BIO-B is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MXCT's competition here
BIO-B vs BWAY Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BWAY has a market cap of 216.8M. Regarding current trading prices, BIO-B is priced at $247.05, while BWAY trades at $11.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BWAY's P/E ratio is 52.14. In terms of profitability, BIO-B's ROE is +0.05%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, BIO-B is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BWAY's competition here
BIO-B vs EYES Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BIO-B is priced at $247.05, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas EYES's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.05%, compared to EYES's ROE of -0.26%. Regarding short-term risk, BIO-B is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EYES's competition here
BIO-B vs CVRX Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, CVRX has a market cap of 197.1M. Regarding current trading prices, BIO-B is priced at $247.05, while CVRX trades at $7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas CVRX's P/E ratio is -3.53. In terms of profitability, BIO-B's ROE is +0.05%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, BIO-B is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CVRX's competition here
BIO-B vs MGRM Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, MGRM has a market cap of 194.9M. Regarding current trading prices, BIO-B is priced at $247.05, while MGRM trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas MGRM's P/E ratio is -10.78. In terms of profitability, BIO-B's ROE is +0.05%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, BIO-B is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MGRM's competition here
BIO-B vs SGHT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, SGHT has a market cap of 169.1M. Regarding current trading prices, BIO-B is priced at $247.05, while SGHT trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas SGHT's P/E ratio is -3.34. In terms of profitability, BIO-B's ROE is +0.05%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, BIO-B is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SGHT's competition here
BIO-B vs INGN Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, INGN has a market cap of 167M. Regarding current trading prices, BIO-B is priced at $247.05, while INGN trades at $6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas INGN's P/E ratio is -5.40. In terms of profitability, BIO-B's ROE is +0.05%, compared to INGN's ROE of -0.15%. Regarding short-term risk, BIO-B is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INGN's competition here
BIO-B vs PROF Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, PROF has a market cap of 165.3M. Regarding current trading prices, BIO-B is priced at $247.05, while PROF trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas PROF's P/E ratio is -4.55. In terms of profitability, BIO-B's ROE is +0.05%, compared to PROF's ROE of -0.70%. Regarding short-term risk, BIO-B is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PROF's competition here
BIO-B vs TLSI Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, TLSI has a market cap of 158.7M. Regarding current trading prices, BIO-B is priced at $247.05, while TLSI trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas TLSI's P/E ratio is -3.80. In terms of profitability, BIO-B's ROE is +0.05%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, BIO-B is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TLSI's competition here
BIO-B vs ELMD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ELMD has a market cap of 151.7M. Regarding current trading prices, BIO-B is priced at $247.05, while ELMD trades at $18.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ELMD's P/E ratio is 22.90. In terms of profitability, BIO-B's ROE is +0.05%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ELMD's competition here
BIO-B vs LNSR Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, LNSR has a market cap of 150.1M. Regarding current trading prices, BIO-B is priced at $247.05, while LNSR trades at $12.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas LNSR's P/E ratio is -2.59. In terms of profitability, BIO-B's ROE is +0.05%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, BIO-B is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LNSR's competition here
BIO-B vs RPID Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, RPID has a market cap of 145.1M. Regarding current trading prices, BIO-B is priced at $247.05, while RPID trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas RPID's P/E ratio is -3.21. In terms of profitability, BIO-B's ROE is +0.05%, compared to RPID's ROE of -0.56%. Regarding short-term risk, BIO-B is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RPID's competition here
BIO-B vs RCEL Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, RCEL has a market cap of 136.4M. Regarding current trading prices, BIO-B is priced at $247.05, while RCEL trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas RCEL's P/E ratio is -2.36. In terms of profitability, BIO-B's ROE is +0.05%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, BIO-B is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RCEL's competition here
BIO-B vs BSGM Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, BSGM has a market cap of 134.4M. Regarding current trading prices, BIO-B is priced at $247.05, while BSGM trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas BSGM's P/E ratio is -8.09. In terms of profitability, BIO-B's ROE is +0.05%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, BIO-B is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSGM's competition here
BIO-B vs ANIK Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ANIK has a market cap of 124.6M. Regarding current trading prices, BIO-B is priced at $247.05, while ANIK trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ANIK's P/E ratio is -9.60. In terms of profitability, BIO-B's ROE is +0.05%, compared to ANIK's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ANIK's competition here
BIO-B vs OWLT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, OWLT has a market cap of 122.1M. Regarding current trading prices, BIO-B is priced at $247.05, while OWLT trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas OWLT's P/E ratio is -4.59. In terms of profitability, BIO-B's ROE is +0.05%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, BIO-B is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check OWLT's competition here
BIO-B vs AVR Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, AVR has a market cap of 114.5M. Regarding current trading prices, BIO-B is priced at $247.05, while AVR trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas AVR's P/E ratio is -0.88. In terms of profitability, BIO-B's ROE is +0.05%, compared to AVR's ROE of -2.92%. Regarding short-term risk, BIO-B is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AVR's competition here
BIO-B vs LUCD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, LUCD has a market cap of 108.2M. Regarding current trading prices, BIO-B is priced at $247.05, while LUCD trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas LUCD's P/E ratio is -0.85. In terms of profitability, BIO-B's ROE is +0.05%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, BIO-B is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LUCD's competition here
BIO-B vs ICAD Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BIO-B is priced at $247.05, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BIO-B's ROE is +0.05%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, BIO-B and ICAD have similar daily volatility (0.00).Check ICAD's competition here
BIO-B vs QIPT Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, QIPT has a market cap of 100.4M. Regarding current trading prices, BIO-B is priced at $247.05, while QIPT trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas QIPT's P/E ratio is -11.00. In terms of profitability, BIO-B's ROE is +0.05%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, BIO-B is less volatile compared to QIPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check QIPT's competition here
BIO-B vs HJLI Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BIO-B is priced at $247.05, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas HJLI's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.05%, compared to HJLI's ROE of -0.57%. Regarding short-term risk, BIO-B is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check HJLI's competition here
BIO-B vs FONR Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, FONR has a market cap of 97M. Regarding current trading prices, BIO-B is priced at $247.05, while FONR trades at $15.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas FONR's P/E ratio is 12.51. In terms of profitability, BIO-B's ROE is +0.05%, compared to FONR's ROE of +0.09%. Regarding short-term risk, BIO-B is less volatile compared to FONR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check FONR's competition here
BIO-B vs ASXC Comparison August 2025
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 6.8B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, BIO-B is priced at $247.05, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -3.23, whereas ASXC's P/E ratio is -1.12. In terms of profitability, BIO-B's ROE is +0.05%, compared to ASXC's ROE of -5.59%. Regarding short-term risk, BIO-B is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ASXC's competition here